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remarkable from 1 week after apex-sacri-
ficing VRS but not in apex-sparing VRS.
Drs Lunkenheimer and Anderson described
in their letter that resection of any part of
LV wall, including the septum, is tolerated
without impairing LV function when the
left ventricle is dilated. However, septal
anterior ventricular exclusion or pacopexy
reduces the septal and anterior wall without
amputating the LV apex and yields good
clinical results.13,14 We think those results
are compatible with our study.
In addition, results of some clinical
cases that underwent the apex-sparing VRS
in our unit have been excellent so far. Thus
we believe that it is important to reduce the
LV volume in dilated left ventricle with
severe LV dysfunction. Apex-sparing VRS
may improve the clinical results.
Although the hypothesis by Dr Torrent-
Guasp and colleagues is very interesting,15
there is no scientific proof so far. Therefore
the relationship between cause and result in
the improved LV function after the apex-
sparing VRS and preservation of single
muscle band is still unknown, and further
study will be required.
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Study of warm perfusion rather than
cardioplegia
To the Editor:
I read the article by Mallidi and col-
leagues,1 “The Short-term and Long-term
Effects of Warm or Tepid Cardioplegia,”
and raise the following concern. The title is
not descriptive of the protocols. Rather
than isolated cold or warm cardioplegia,
the article really describes cold and warm
total-body and cardiac perfusion strategies.
The article states, “In the warm or tepid
blood cardioplegia group, the systemic
temperature was maintained at 33°C to
37°C, and the blood cardioplegia was de-
livered at a temperature of 37°C. In the
tepid cardioplegia group, the systemic tem-
perature was permitted to drift passively
during the operation to 32°C to 34°C. The
temperature of the cardioplegia was 28° to
30°C. In the cold cardioplegia group, the
systemic temperature was actively cooled
to 25°C to 32°C, and the blood cardiople-
gia was actively cooled to a temperature of
5°C to 8°C.”
Other combinations may have similar
results, for example a warm corporeal per-
fusion strategy (drifting without active
cooling) and cold cardioplegia. The data do
not preclude such a result.
This group has done a nice job scientif-
ically studying and promoting warm perfu-
sion and protection strategies. I think that
describing their technique as “warm blood
cardioplegia” does not describe the strategy
adequately, and “warm perfusion strategy”
might be more accurate.
Edward B. Savage, MD
Rush–Presbyterian–St Luke’s Medical Center
Chicago, IL 60612
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Reply to the Editor:
Dr Savage correctly points out that the ar-
ticle published in the March issue of the
Journal by our group was not simply a
comparison of cold versus warm or tepid
cardioplegia, but rather a comparison of the
strategy of warm or tepid cardioplegia ver-
sus cold cardioplegia. The three cardiople-
gic and systemic perfusion strategies used
in patients undergoing isolated coronary
artery grafting surgery at our institution
were described in detail in the article. Other
possible cardioplegic and systemic perfu-
sion strategies (such as warm systemic per-
fusion with cold cardioplegia, tepid sys-
temic perfusion with cold cardioplegia,
systemic hypothermia with warm or tepid
cardioplegia, and so on) were not used in
our institution.
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One potential reason for avoiding strat-
egies that have mixed cardioplegia and sys-
temic perfusion temperatures (cold for one
with warm or tepid for the other) is the
concern that the myocardial temperature in
the mixed temperatures situation would
likely result in highly variable and incon-
sistent myocardial temperatures.1 It has
been demonstrated that the delivery of cold
cardioplegia results in decreased subepicar-
dial and midwall ventricular perfusion.
This datum, coupled with information that
myocardial temperature is variable with
cold cardioplegia, suggests that myocardial
protection may be compromised by such a
mixed temperature environment.2
However, others have shown no in-
crease in the release of myocardial injury
markers (troponin I and T) after normother-
mic systemic perfusion relative to hypo-
thermic systemic perfusion when a regimen
of cold cardioplegia with topical cooling
was used for myocardial protection, and
acceptable clinical results are possible.3
Furthermore, acceptable clinical results
have been reported with the technique of
cold cardioplegia with warm systemic per-
fusion.4 Thus considerable controversy
continues to exist regarding whether cold
cardioplegia with warm systemic perfusion
is harmful; however, there are no studies
demonstrating its superiority to the strategy
of warm cardioplegia with tepid systemic
perfusion.
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Nickel allergy to the percutaneous
patent foramen ovale occluder and
subsequent systemic nickel allergy
To the Editor:
We read with great interest the article
“Systemic Allergic Reaction to the Per-
cutaneous Patent Foramen Ovale Oc-
cluder” by Fukahara and colleagues.1 In
that article, Fukahara and colleagues1 de-
scribed the case of a 37-year-old patient
who underwent patent foramen ovale clo-
sure with the Star device (Cardia Inc,
Burnsville, Minn). In the following 2
months, the patient began demonstrating
hypersensitivity to the device, confirmed
by skin patch testing as an allergy to
nitinol. Removal of the device ultimately
led to this patient’s recovery.
In October 2001, we treated an 11-year-
old boy who had undergone transcatheter
closure of a secundum type atrial septal
defect with the HELEX Septal Occluder
(W.L. Gore and Associates, Flagstaff,
Ariz).2 Similar to Fukahara and colleagues’
patient, our patient had a similar reaction to
the device; he ultimately had positive skin
patch test results for nickel allergy. This
patient underwent uneventful removal of
the device as well but also required subse-
quent removal of the sternal wires, which
had trace amounts of nickel. This patient
was initially unavailable for follow-up at
our institution. To our knowledge, how-
ever, he has had an otherwise uneventful
recovery.
We thank Fukahara and colleagues1 for
their report on the subject. We encourage
the cardiothoracic community at large to
report such events to determine objectively
the incidence of adverse outcomes that may
be associated with these emerging technol-
ogies.
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Activated prothrombin complex
concentrates and recombinant factor
VIIa in the bleeding patient: Are they
appropriate and safe?
To the Editor:
I read with great interest the article of Bui
and colleagues,1 “Fatal Thrombosis After
Administration of Activated Prothrombin
Complex Concentrates in a Patient Sup-
ported by Extracorporeal Membrane Ox-
ygenation Who Had Received Activated
Recombinant Factor VII,” in the October
2002 Journal. Many issues related to the
administration of activated prothrombin
complex concentrates presented by this
case were too simply discussed.
First, the patient had evidence of dis-
seminated intravascular coagulation both
before the cessation of heparin and after its
discontinuation, with prolonged prothrom-
bin time and partial thromboplastin time.
No data are available regarding the pa-
tient’s platelet count before or after surgi-
cal intervention. Both recombinant factor
VIIa and factor VIII bypassing activity
(FEIBA) were used off-label, about which
the authors made little comment. Cardiac
surgery with extracorporeal membrane ox-
ygenation is known to activate clotting, and
death might well have occurred even with-
out either biologic agent. The cardiac death
may not have been from thrombus, but of
another origin; because no autopsy was
performed, however, all this is pure spec-
ulation.
The authors stated with great conviction
that thrombosis with recombinant factor
VIIa is less common than with FEIBA.
Continued hemorrhage itself is a cause of
activation of coagulation. Agents known to
aid in stopping hemorrhage in patients with
coagulation defects have caused throm-
botic episodes.
Almost all the life-threatening throm-
botic events with FEIBA have occurred
with doses exceeding those recommend-
ed.2 Bui and colleagues1 provided no data
regarding the dose of FEIBA given.
Thrombotic events, including myocardial
Letters to the Editor
2112 The Journal of Thoracic and Cardiovascular Surgery ● December 2003
